Scotiabank analyst George Farmer last night initiated coverage of Tempest Therapeutics with an Outperform rating and $13 price target. The analyst recommends buying shares of Tempest to capture the value potential of its lead oral small molecule, TPST-1120, for the treatment of advanced unresectable hepatocellular carcinoma, a subset of liver cancer. The firm says Phase 2 clinical trial results show a “compelling” improvement in overall survival when used in combination with standard-of-care in patients with intermediate- to high-risk disease, which highly supports the potential clinical utility of ‘1120 as first-line treatment.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TPST:
- Tempest Therapeutics presents new data on TPST-1120 at SITC meeting
- Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
- Tempest Therapeutics initiated with a Buy at Jefferies
- Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Largest borrow rate increases among liquid names
